DIVI'S LABORATORIES LTD. - 532488 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Submission of Postal Ballot Notice dated February 10, 2024.04-03-2024
04-03-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We herewith enclose the Transcript of earnings conference call held on February 10, 2024.16-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper publication12-02-2024
Q3FY24 Quarterly & 9MFY24 Result Announced for Divi's Laboratories Ltd.
Pharmaceuticals company Divi's Laboratories announced Q3FY24 & 9MFY24 results: Consolidated Q3FY24: Total Income: Rs 1,950 crore, compared to Rs 1,821 crore in the corresponding quarter of the previous year. Material Consumption: Approximately 39% of sales revenue. Profit Before Tax (PBT): Rs 489 crore, compared to Rs 435 crore in the corresponding quarter of the previous year. Profit After Tax (PAT): Rs 358 crore, compared to Rs 306 crore in the corresponding quarter of the previous year. Standalone Q3FY24: Total Income: Recorded at Rs 1,902 crore in Q3FY24 compared to Rs 1,807 crore in Q3FY23. Profit Before Tax (PBT): Stood at Rs 490 crore in Q3FY24, up from Rs 439 crore in Q3FY23. Profit After Tax (PAT): Amounted to Rs 358 crore in Q3FY24, higher than the Rs 310 crore in Q3FY23. Forex Gain: Registered at Rs 17 crore in Q3FY24, decreased from Rs 49 crore in Q3FY23. Consolidated 9MFY24: Total Income: Rs 5,804 crore, compared to Rs 6,099 crore in the corresponding previous period. Profit After Tax (PAT): Rs 1,062 crore, compared to Rs 1,502 crore in the corresponding previous period. Forex Gain: Rs 32 crore, compared to Rs 134 crore in the previous 9-month period. Standalone 9MFY24: Total Income: For 9MFY24, it amounted to Rs 5,665 crore, down from Rs 6,003 crore in 9MFY23. Profit Before Tax (PBT): For 9MFY24, it was Rs 1,432 crore, a decrease from Rs 1,886 crore in 9MFY23. Profit After Tax (PAT): For 9MFY24, it reached Rs 1,045 crore, down from Rs 1,489 crore in 9MFY23. Forex Gain: For 9MFY24, it stood at Rs 29 crore, a decline from Rs 137 crore in 9MFY23. Result PDF12-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
We hereby inform that the audio recording of the earnings call for Q3FY24 held on February 10, 2024 has been updated on the Company''s website.10-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Change in Directorate
As per enclosed attachment.10-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On February 10, 2024
As per enclosed attachment.10-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Nine Months Ended December 31, 2023
As per enclsoed attachment.10-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of earnings conference call for the quarter and nine months ended December 31, 2023 to be held on February 10, 2024 at 14:00 hrs (IST).02-02-2024
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Considering And Approving The Standalone And Consolidated Unaudited Financial Results For The Quarter And Nine Months Ended December 31, 2023
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2024 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 202330-01-2024